Effect of Belimumab on Preventing de novo Renal Lupus Flares.

ABSTRACT:

Introduction

Belimumab was recently approved for treating lupus nephritis (LN), yet de novo LN cases during belimumab treatment given for nonrenal causes have been reported. Identification of reliable signals of impending flare is imperative.

Methods

We evaluated belimumab efficacy in preventing de novo renal flares and factors associated with renal flare occurrence in nephritis-naïve patients with systemic lupus erythematosus (SLE) who are receiving add-on belimumab or placebo in 5 phase 3 clinical trials using Cox regression analysis.

Results

Of 1844 eligible patients, 136 (7.4%) developed a de novo renal flare during a 52-week long follow-up. Asian origin (Adjusted Hazard Ratio [HR_adj]: 1.97; 95% confidence interval [CI]: 1.32-2.94;

SUBMITTER: Parodis I 

PROVIDER: S-EPMC10496079 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature